Synovus Financial Corp Grows Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Synovus Financial Corp lifted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 13.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,639 shares of the medical equipment provider’s stock after purchasing an additional 3,038 shares during the quarter. Synovus Financial Corp’s holdings in Lantheus were worth $2,294,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB purchased a new position in Lantheus in the third quarter worth about $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $27,000. Summit Securities Group LLC purchased a new position in Lantheus in the 4th quarter worth approximately $37,000. UMB Bank n.a. boosted its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC bought a new stake in shares of Lantheus in the 3rd quarter worth $60,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of LNTH stock opened at $102.13 on Tuesday. Lantheus Holdings, Inc. has a 1 year low of $59.56 and a 1 year high of $126.89. The firm has a fifty day moving average price of $94.24 and a 200-day moving average price of $95.53. The company has a market cap of $6.99 billion, a price-to-earnings ratio of 16.99 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,109 shares of company stock worth $6,110,806. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. B. Riley dropped their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.